ArticleJournal of the Canadian Association of Gastroenterology2021

A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn's Disease.

Avery Hughes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.